Core Viewpoint - Santhera Pharmaceuticals has successfully closed a USD 13 million royalty monetization agreement to support the global launch of AGAMREE® (vamorolone) [1][4]. Group 1: Agreement Details - The royalty monetization agreement was initially secured in September 2025 with R-Bridge, covering 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals in North America and Sperogenix Therapeutics in China [2]. - Partners Group, a major player in the global private markets, has joined the financing, contributing a majority of the USD 13 million raised [2]. - Payments to Partners Group and R-Bridge are capped, and once the ceiling or duration is reached, royalties revert to Santhera [3]. Group 2: Company Background - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing innovative medicines for rare neuromuscular diseases with high unmet medical needs [4]. - The company holds an exclusive license for AGAMREE® (vamorolone), which is approved for treating Duchenne muscular dystrophy (DMD) in multiple regions including the U.S., EU, UK, China, Hong Kong, and Canada [4].